Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Wakayama Substance Supplier Mixed in China-Made Ingredient; MHLW Sees No Safety Concerns
June 23, 2017
- 3 Independent Administrative Agencies Will Have Access to Research Funding from Outside Initial Budgets
June 23, 2017
- Pharmaceuticals, Medical Devices Unlikely to Be Focus of Japan-EU EPA
June 22, 2017
- Draft Guideline on Lifecycle Management Reaches Agreement at ICH Meeting in Montreal
June 22, 2017
- JMA Plans Chuikyo Rep Reshuffle, Nakagawa Likely to Bow Out
June 21, 2017
- PMDA Beats FY2016 Review Time Targets
June 16, 2017
- CDISC-Based Electronic Submissions for 24 Products in FY2016: PMDA
June 16, 2017
- 15.3 Billion Yen to Be Allocated to 30 Projects to Promote R&D in Field of Healthcare
June 16, 2017
- MHLW Panel Recommends Moving Ahead with Discussions toward Easing Regulations on Export of Blood Products
June 16, 2017
- MHLW Tries to Give Full Picture of Envisaged “CEA” Scheme with Hypothetical Drug: Chuikyo
June 15, 2017
- 1st Generics for 13 APIs to Join NHI Price List on June 16; Micardis, Abilify Face Competition
June 15, 2017
- Daiichi Sanko Espha Skips June Listing for Rezaltas, Gracevit AGs
June 15, 2017
- Chuikyo Reps Agree on Revisiting Discrepancy Rate Cutoff for Price Maintenance Premium
June 15, 2017
- Chuikyo Members Want to Stick to Pilot-Based Premium, at Odds with Industry
June 15, 2017
- (Update) Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium, Tiered Premiums Eyed: Chuikyo
June 15, 2017
- Chuikyo OKs Plan for FY2017 Drug Price Survey
June 14, 2017
- Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium: Chuikyo
June 14, 2017
- PMDA Provides Relief for Over 100 Health Damage Cases Tied to HPV Vaccines: FY2016
June 13, 2017
- MHLW Panel Gives Thumbs-Up for Nusinersen, Tenelia-Canaglu Combo
June 12, 2017
- MHLW Study Group on Counterfeit Drugs to Discuss Issues such as GDP Later This Fiscal Year
June 12, 2017
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…